(Pyrroloquinoxalinyl) pyrazinecarbohydrazide-oxalic acid co-crystal for treatment of cancer and other diseases
A novel co-crystal of N′-(7-fluoropyrrolo[1,2a]quinoxalin-4-yl)pyrazine-2-carbohydrazide with oxalic acid is disclosed. The disclosed oxalic acid co-crystal demonstrates cancer cell growth inhibition and is more bioavailable than the corresponding free base when administered as a suspension.
1. A co-crystal of N′-(7-fluoropyrrolo[1,2a]quinoxalin-4-yl)pyrazine-2-carbohydrazide and oxalic acid.
2. A method of preparing the co-crystal of claim 1 comprising: adding an aqueous solution of oxalic acid to an aqueous solution of N′-(7-fluoropyrrolo[1,2a]quinoxalin-4-yl)pyrazine-2-carbohydrazide.
3. A method of treating breast cancer in a human or an animal comprising, identifying a human or animal in need thereof, and administering the co-crystal of claim 1 to said human or animal.
4. The method of claim 3 , wherein the co-crystal of claim 1 is administered in a quantity sufficient to treat the breast cancer.
5. The method of claim 4 , wherein the co-crystal is administered orally.
6. The method of claim 4 , wherein the co-crystal is administered parenterally.
7. The method of claim 4 , wherein the co-crystal is administered topically.
8. The method of claim 4 , wherein the co-crystal is administered to a human.
9. The method of claim 4 , wherein the co-crystal is administered to an animal.
10. A pharmaceutical preparation comprising the co-crystal of claim 1 .
11. A method of treating breast cancer comprising administering the pharmaceutical preparation of claim 10 .
12. A composition comprising the co-crystal of claim 1 and a pharmaceutical excipient.